Adults

For 250 mg strength, it is usually 250 mg IV every 8 hours for specific susceptible infections, or as directed by a physician. Doses may range from 500 mg to 1 g IV every 8 hours for more severe infections, based on infection type and severity.

Elderly

Dosage adjustment is recommended in elderly patients based on renal function (creatinine clearance).

Renal_impairment

Dose adjustment required based on creatinine clearance: e.g., CrCl 26-50 mL/min: 250 mg every 12 hours; CrCl 10-25 mL/min: 250 mg every 24 hours. Hemodialysis patients should receive dose after dialysis.

Onset

Rapid, typically within minutes of IV administration.

Excretion

Primarily renal, with approximately 70% eliminated unchanged in urine within 12 hours. Hemodialysis removes meropenem.

Half life

Approximately 1 hour in adults with normal renal function.

Absorption

Rapidly absorbed after intravenous (IV) administration. Peak plasma concentration achieved at the end of infusion.

Metabolism

Minimally metabolized; about 20% by hydrolysis of the beta-lactam ring to an inactive metabolite.

Probenecid

Increases meropenem plasma concentrations and prolongs its half-life by inhibiting renal tubular secretion.

Valproic Acid / Sodium Valproate

Meropenem may decrease serum concentrations of valproic acid, potentially leading to loss of seizure control. Co-administration is generally not recommended.

Oral Anticoagulants (e.g., Warfarin)

Concomitant use with antibiotics including carbapenems has been reported to increase anticoagulant effect. Regular monitoring of INR is advised.